Clinical Study Demonstrates That Cardiola’s M.Pulse(R) System “Immediately Improves Cardiac Output Under Acute Non-Invasive Muscular Counterpulsation (MCP) Treatment In Patients With Patients With Stable CHF” (Chronic Heart Failure)

WINTERTHUR, Switzerland--(BUSINESS WIRE)--Cardiola AG announced today that the Company’s CE-Marked m.pulse® Muscular CounterPulsation (“MCP”)-based system demonstrated “an immediate improvement of cardiac output with non-invasive means” in a patient population of advanced yet stable chronic heart failure. The effects could be shown in 22 patients over three consecutive days.